Scheffler Richard M, Hinshaw Stephen P, Modrek Sepideh, Levine Peter
Nicholas C. Petris Center on Health Care Markets and Consumer Welfare, University of California, Berkeley, CA, USA.
Health Aff (Millwood). 2007 Mar-Apr;26(2):450-7. doi: 10.1377/hlthaff.26.2.450.
Little is known about the global use and cost of medications for attention deficit hyperactivity disorder (ADHD). Global use of ADHD medications rose threefold from 1993 through 2003, whereas global spending (2.4 billion US dollars in 2003) rose ninefold, adjusting for inflation. Per capita gross domestic product (GDP) robustly predicted use across countries, but the United States, Canada, and Australia showed significantly higher-than-predicted use. Use and spending grew in both developed and developing countries, but spending growth was concentrated in developed countries, which adopted more costly, long-acting formulations. Promoting optimal prescription and monitoring should be a priority.
关于注意力缺陷多动障碍（ADHD）药物的全球使用情况和成本，人们所知甚少。从1993年到2003年，全球ADHD药物的使用量增长了两倍，而经通胀调整后，全球支出（2003年为24亿美元）增长了九倍。人均国内生产总值（GDP）有力地预测了各国的药物使用情况，但美国、加拿大和澳大利亚的使用量明显高于预测值。发达国家和发展中国家的使用量和支出均有所增长，但支出增长集中在发达国家，这些国家采用了成本更高的长效制剂。促进优化处方和监测应成为首要任务。
